172 related articles for article (PubMed ID: 36933158)
1. lncRNA miR4458HG modulates hepatocellular carcinoma progression by activating m6A-dependent glycolysis and promoting the polarization of tumor-associated macrophages.
Ye Y; Wang M; Wang G; Mai Z; Zhou B; Han Y; Zhuang J; Xia W
Cell Mol Life Sci; 2023 Mar; 80(4):99. PubMed ID: 36933158
[TBL] [Abstract][Full Text] [Related]
2. LncRNA FTO-IT1 promotes glycolysis and progression of hepatocellular carcinoma through modulating FTO-mediated N6-methyladenosine modification on GLUT1 and PKM2.
Wang F; Hu Y; Wang H; Hu P; Xiong H; Zeng Z; Han S; Wang D; Wang J; Zhao Y; Huang Y; Zhuo W; Lv G; Zhao G
J Exp Clin Cancer Res; 2023 Oct; 42(1):267. PubMed ID: 37840133
[TBL] [Abstract][Full Text] [Related]
3. The m6A modification-mediated positive feedback between glycolytic lncRNA SLC2A1-DT and c-Myc promotes tumorigenesis of hepatocellular carcinoma.
Zeng Z; Wang J; Xu F; Hu P; Hu Y; Zhuo W; Chen D; Han S; Wang F; Zhao Y; Huang Y; Zhao G
Int J Biol Sci; 2024; 20(5):1744-1762. PubMed ID: 38481809
[TBL] [Abstract][Full Text] [Related]
4. Long noncoding RNA SLC2A1-AS1 regulates aerobic glycolysis and progression in hepatocellular carcinoma via inhibiting the STAT3/FOXM1/GLUT1 pathway.
Shang R; Wang M; Dai B; Du J; Wang J; Liu Z; Qu S; Yang X; Liu J; Xia C; Wang L; Wang D; Li Y
Mol Oncol; 2020 Jun; 14(6):1381-1396. PubMed ID: 32174012
[TBL] [Abstract][Full Text] [Related]
5. Tumor associated macrophages-derived exosomes facilitate hepatocellular carcinoma malignance by transferring lncMMPA to tumor cells and activating glycolysis pathway.
Xu M; Zhou C; Weng J; Chen Z; Zhou Q; Gao J; Shi G; Ke A; Ren N; Sun H; Shen Y
J Exp Clin Cancer Res; 2022 Aug; 41(1):253. PubMed ID: 35986343
[TBL] [Abstract][Full Text] [Related]
6. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis.
Wang Y; Yang L; Chen T; Liu X; Guo Y; Zhu Q; Tong X; Yang W; Xu Q; Huang D; Tu K
Mol Cancer; 2019 Feb; 18(1):28. PubMed ID: 30782188
[TBL] [Abstract][Full Text] [Related]
7. LNCAROD enhances hepatocellular carcinoma malignancy by activating glycolysis through induction of pyruvate kinase isoform PKM2.
Jia G; Wang Y; Lin C; Lai S; Dai H; Wang Z; Dai L; Su H; Song Y; Zhang N; Feng Y; Tang B
J Exp Clin Cancer Res; 2021 Sep; 40(1):299. PubMed ID: 34551796
[TBL] [Abstract][Full Text] [Related]
8. Long noncoding RNA LINC00662 promotes M2 macrophage polarization and hepatocellular carcinoma progression via activating Wnt/β-catenin signaling.
Tian X; Wu Y; Yang Y; Wang J; Niu M; Gao S; Qin T; Bao D
Mol Oncol; 2020 Feb; 14(2):462-483. PubMed ID: 31785055
[TBL] [Abstract][Full Text] [Related]
9. Circular RNA MAT2B Promotes Glycolysis and Malignancy of Hepatocellular Carcinoma Through the miR-338-3p/PKM2 Axis Under Hypoxic Stress.
Li Q; Pan X; Zhu D; Deng Z; Jiang R; Wang X
Hepatology; 2019 Oct; 70(4):1298-1316. PubMed ID: 31004447
[TBL] [Abstract][Full Text] [Related]
10. LncRNA MYLK-AS1 facilitates tumor progression and angiogenesis by targeting miR-424-5p/E2F7 axis and activating VEGFR-2 signaling pathway in hepatocellular carcinoma.
Teng F; Zhang JX; Chang QM; Wu XB; Tang WG; Wang JF; Feng JF; Zhang ZP; Hu ZQ
J Exp Clin Cancer Res; 2020 Nov; 39(1):235. PubMed ID: 33168027
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-inducible long noncoding RNA NPSR1-AS1 promotes the proliferation and glycolysis of hepatocellular carcinoma cells by regulating the MAPK/ERK pathway.
He H; Chen T; Mo H; Chen S; Liu Q; Guo C
Biochem Biophys Res Commun; 2020 Dec; 533(4):886-892. PubMed ID: 33008585
[TBL] [Abstract][Full Text] [Related]
12. IGF2BP2 promotes glycolysis and hepatocellular carcinoma stemness by stabilizing CDC45 mRNA via m6A modification.
Wu T; Liao L; Wu T; Chen S; Yi Q; Xu M
Cell Cycle; 2023 Oct; 22(20):2245-2263. PubMed ID: 37985379
[TBL] [Abstract][Full Text] [Related]
13. LncRNA HOTAIR knockdown inhibits glycolysis by regulating miR-130a-3p/HIF1A in hepatocellular carcinoma under hypoxia.
Hu M; Fu Q; Jing C; Zhang X; Qin T; Pan Y
Biomed Pharmacother; 2020 May; 125():109703. PubMed ID: 32062551
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the long non-coding RNA SPRY4-IT1 promotes tumor cell proliferation and invasion by activating EZH2 in hepatocellular carcinoma.
Zhou M; Zhang XY; Yu X
Biomed Pharmacother; 2017 Jan; 85():348-354. PubMed ID: 27899259
[TBL] [Abstract][Full Text] [Related]
15. LINC01554-Mediated Glucose Metabolism Reprogramming Suppresses Tumorigenicity in Hepatocellular Carcinoma via Downregulating PKM2 Expression and Inhibiting Akt/mTOR Signaling Pathway.
Zheng YL; Li L; Jia YX; Zhang BZ; Li JC; Zhu YH; Li MQ; He JZ; Zeng TT; Ban XJ; Yuan YF; Li Y; Guan XY
Theranostics; 2019; 9(3):796-810. PubMed ID: 30809309
[No Abstract] [Full Text] [Related]
16. Long non-coding RNAs HERH-1 and HERH-4 facilitate cyclin A2 expression and accelerate cell cycle progression in advanced hepatocellular carcinoma.
Liu T; Shi Q; Yang L; Wang S; Song H; Wang Z; Xu X; Liu H; Zheng H; Shen Z
BMC Cancer; 2021 Aug; 21(1):957. PubMed ID: 34445994
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA TPTEP1 inhibits hepatocellular carcinoma progression by suppressing STAT3 phosphorylation.
Ding H; Liu J; Zou R; Cheng P; Su Y
J Exp Clin Cancer Res; 2019 May; 38(1):189. PubMed ID: 31072375
[TBL] [Abstract][Full Text] [Related]
18. Exosomal lncRNA HEIH, an essential communicator for hepatocellular carcinoma cells and macrophage M2 polarization through the miR-98-5p/STAT3 axis.
Ai JH; Wen YZ; Dai SJ; Zhang LD; Huang ZJ; Shi J
J Biochem Mol Toxicol; 2024 Apr; 38(4):e23686. PubMed ID: 38549433
[TBL] [Abstract][Full Text] [Related]
19. A novel lncRNA RP11-386G11.10 reprograms lipid metabolism to promote hepatocellular carcinoma progression.
Xu K; Xia P; Gongye X; Zhang X; Ma S; Chen Z; Zhang H; Liu J; Liu Y; Guo Y; Yao Y; Gao M; Chen Y; Zhang Z; Yuan Y
Mol Metab; 2022 Sep; 63():101540. PubMed ID: 35798238
[TBL] [Abstract][Full Text] [Related]
20. Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2.
Zhang DY; Sun QC; Zou XJ; Song Y; Li WW; Guo ZQ; Liu SS; Liu L; Wu DH
J Exp Clin Cancer Res; 2020 Oct; 39(1):229. PubMed ID: 33121524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
